中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 2
Feb.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(2): 278-285

Research advances in antiviral drugs for the treatment of hepatitis D virus infection

DOI: 10.12449/JCH260205
  • 1.

    Huahui Health Ltd.，Beijing 102206，China

  • 2.

    National Institute of Biological Sciences，Beijing 102206，China

  • 3.

    Tsinghua Institute of Multidisciplinary Biomedical Research，Tsinghua University，Beijing 100084，China

More Information
  • Corresponding author: SUI Jianhua， suijianhua@hhhbio.com （ORCID： 0000-0002-1272-9662）; LI Wenhui， liwenhui@nibs.ac.cn （ORCID： 0000-0003-1305-7404）
  • Received Date: 2026-01-27
  • Accepted Date: 2026-02-13
  • Published Date: 2026-02-25
    Abstract
  • Co-infection of hepatitis D virus （HDV） and hepatitis B virus （HBV） is the most severe form of viral hepatitis and is associated with accelerated progression of liver disease and a significant increase in the risk of liver cirrhosis and hepatocellular carcinoma. Nucleo（s）tide analogues for HBV treatment are ineffective against HDV infection， necessitating the urgent need for developing specific and effective antiviral therapies for HDV. In recent years， significant advances have been made in the research and development of specific antiviral drugs against HDV， including entry inhibitors targeting viral entry （Bulevirtide） and monoclonal antibody drugs （Libevitug）， which bring ground-breaking advances in the treatment of HDV infection. This article briefly reviews the latest research advances in therapeutic drugs for HDV， introduces the mechanism of action and clinical research data of new drugs recently approved for the treatment of HDV， and discusses the challenges that need to be solved in the field of HDV treatment， in order to provide a reference for understanding the current status of hepatitis D treatment.

     

    • FullText(HTML)
  • loading
    • References(67)
  • [1]
    MIAO ZJ, ZHANG SS, OU XM, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection[J]. J Infect Dis, 2020, 221( 10): 1677- 1687. DOI: 10.1093/infdis/jiz633.
    [2]
    ASSELAH T, RIZZETTO M. Hepatitis D virus infection[J]. N Engl J Med, 2023, 389( 1): 58- 70. DOI: 10.1056/nejmra2212151.
    [3]
    World Health Organization. Global hepatitis report 2024: Action for access in low- and middle-income countries[R]. Geneva: World Health Organization, 2024.
    [4]
    ZHANG ZF, URBAN S. New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies[J]. J Hepatol, 2021, 74( 3): 686- 699. DOI: 10.1016/j.jhep.2020.11.032.
    [5]
    WEDEMEYER H, YURDAYDÌN C, DALEKOS GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta[J]. N Engl J Med, 2011, 364( 4): 322- 331. DOI: 10.1056/NEJMoa0912696.
    [6]
    FARCI P, MANDAS A, COIANA A, et al. Treatment of chronic hepatitis D with interferon Alfa-2a[J]. N Engl J Med, 1994, 330( 2): 88- 94. DOI: 10.1056/NEJM199401133300202.
    [7]
    CASTELNAU C, LE GAL F, RIPAULT MP, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RT-PCR for follow-up[J]. Hepatology, 2006, 44( 3): 728- 735. DOI: 10.1002/hep.21325.
    [8]
    HEIDRICH B, YURDAYDıN C, KABAÇAM G, et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta[J]. Hepatology, 2014, 60( 1): 87- 97. DOI: 10.1002/hep.27102.
    [9]
    WRANKE A, HARDTKE S, HEIDRICH B, et al. Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta[J]. J Viral Hepat, 2020, 27( 12): 1359- 1368. DOI: 10.1111/jvh.13366.
    [10]
    RIZZETTO M, CANESE MG, ARICÒ S, et al. Immunofluorescence detection of new antigen-antibody system(delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers[J]. Gut, 1977, 18( 12): 997- 1003. DOI: 10.1136/gut.18.12.997.
    [11]
    FLORES R, OWENS RA, TAYLOR J. Pathogenesis by subviral agents: Viroids and hepatitis delta virus[J]. Curr Opin Virol, 2016, 17: 87- 94. DOI: 10.1016/j.coviro.2016.01.022.
    [12]
    URBAN S, NEUMANN-HAEFELIN C, LAMPERTICO P. Hepatitis D virus in 2021: Virology, immunology and new treatment approaches for a difficult-to-treat disease[J]. Gut, 2021, 70( 9): 1782- 1794. DOI: 10.1136/gutjnl-2020-323888.
    [13]
    HOYER B, BONINO F, PONZETTO A, et al. Properties of delta-associated ribonucleic acid[J]. Prog Clin Biol Res, 1983, 143: 91- 97.
    [14]
    YAN H, ZHONG GC, XU GW, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J]. eLife, 2012, 1: e00049. DOI: 10.7554/eLife.00049.
    [15]
    CHAO M, HSIEH SY, TAYLOR J. Role of two forms of hepatitis delta virus antigen: Evidence for a mechanism of self-limiting genome replication[J]. J Virol, 1990, 64( 10): 5066- 5069. DOI: 10.1128/JVI.64.10.5066-5069.1990.
    [16]
    SUREAU C, GUERRA B, LANFORD RE. Role of the large hepatitis B virus envelope protein in infectivity of the hepatitis delta virion[J]. J Virol, 1993, 67( 1): 366- 372. DOI: 10.1128/JVI.67.1.366-372.1993.
    [17]
    SUREAU C, NEGRO F. The hepatitis delta virus: Replication and pathogenesis[J]. J Hepatol, 2016, 64( 1 Suppl): S102- S116. DOI: 10.1016/j.jhep.2016.02.013.
    [18]
    STOCKDALE AJ, KREUELS B, HENRION MYR, et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis[J]. J Hepatol, 2020, 73( 3): 523- 532. DOI: 10.1016/j.jhep.2020.04.008.
    [19]
    PALOM A, RODRÍGUEZ-TAJES S, NAVASCUÉS CA, et al. Long-term clinical outcomes in patients with chronic hepatitis delta: The role of persistent viraemia[J]. Aliment Pharmacol Ther, 2020, 51( 1): 158- 166. DOI: 10.1111/apt.15521.
    [20]
    RIZZETTO M. Chronic hepatitis D; at a standstill[J]. Dig Dis, 2016, 34( 4): 303- 307. DOI: 10.1159/000444467.
    [21]
    YURDAYDIN C, ABBAS Z, BUTI M, et al. Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy[J]. J Hepatol, 2019, 70( 5): 1008- 1015. DOI: 10.1016/j.jhep.2018.12.022.
    [22]
    KARAIVAZOGLOU K, ICONOMOU G, TRIANTOS C, et al. Fatigue and depressive symptoms associated with chronic viral hepatitis patients’ health-related quality of life(HRQOL)[J]. Ann Hepatol, 2010, 9( 4): 419- 427. DOI: 10.1016/S1665-2681(19)31618-7.
    [23]
    ROMEO R, FOGLIENI B, CASAZZA G, et al. High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta[J]. PLoS One, 2014, 9( 3): e92062. DOI: 10.1371/journal.pone.0092062.
    [24]
    FATTOVICH G, BOSCARO S, NOVENTA F, et al. Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B[J]. J Infect Dis, 1987, 155( 5): 931- 935. DOI: 10.1093/infdis/155.5.931.
    [25]
    ROMEO R, DEL NINNO E, RUMI M, et al. A 28-year study of the course of hepatitis Delta infection: A risk factor for cirrhosis and hepatocellular carcinoma[J]. Gastroenterology, 2009, 136( 5): 1629- 1638. DOI: 10.1053/j.gastro.2009.01.052.
    [26]
    European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2025, 83( 2): 502- 583. DOI: 10.1016/j.jhep.2025.03.018.
    [27]
    ZUO SN, ZHAO JZ. Current status and considerations of clinical development of new drugs for the treatment of hepatitis D[J]. Chin J Clin Pharmacol, 2024, 40( 3): 464- 471. DOI: 10.13699/j.cnki.1001-6821.2024.03.033.

    左书凝, 赵建中. 丁型病毒性肝炎治疗新药临床研发现状及考量[J]. 中国临床药理学杂志, 2024, 40( 3): 464- 471. DOI: 10.13699/j.cnki.1001-6821.2024.03.033.
    [28]
    GHANY MG, BUTI M, LAMPERTICO P, et al. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference[J]. Hepatology, 2023, 78( 5): 1654- 1673. DOI: 10.1097/HEP.0000000000000431.
    [29]
    GRIPON P, CANNIE I, URBAN S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein[J]. J Virol, 2005, 79( 3): 1613- 1622. DOI: 10.1128/JVI.79.3.1613-1622.2005.
    [30]
    ENGELKE M, MILLS K, SEITZ S, et al. Characterization of a hepatitis B and hepatitis delta virus receptor binding site[J]. Hepatology, 2006, 43( 4): 750- 760. DOI: 10.1002/hep.21112.
    [31]
    European Association for the Study of the Liver. EASL clinical practice guidelines on hepatitis delta virus[J]. J Hepatol, 2023, 79( 2): 433- 460. DOI: 10.1016/j.jhep.2023.05.001.
    [32]
    WEDEMEYER H, ALEMAN S, BRUNETTO MR, et al. A phase 3, randomized trial of bulevirtide in chronic hepatitis D[J]. N Engl J Med, 2023, 389( 1): 22- 32. DOI: 10.1056/NEJMoa2213429.
    [33]
    LAMPERTICO P, ALEMAN S, BRUNETTO M, et al. P135 Efficacy and safety of 144 weeks of bulevirtide 2 mg or 10 mg monotherapy from the ongoing phase 3 study, MYR301[J]. Gut, 2024, 73( 3): A96– A97. DOI: 10.1136/gutjnl-2024-BASL.137.
    [34]
    WEDEMEYER H, ALEMAN S, BLANK A, et al. P158 Final results of MYR301: A randomised phase 3 study evaluating the efficacy and safety of up to 144 weeks of bulevirtide monotherapy for chronic hepatitis delta and 96 weeks of posttreatment follow-up[J]. Gut, 2025, 74( 4): A117. DOI: 10.1136/gutjnl-2025-BASL.168.
    [35]
    DEGASPERI E, ANOLLI MP, JACHS M, et al. Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis[J]. J Hepatol, 2025, 82( 6): 1012- 1022. DOI: 10.1016/j.jhep.2024.12.044.
    [36]
    DIETZ-FRICKE C, DEGASPERI E, JACHS M, et al. Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-a real-world case series[J]. Hepatology, 2024, 80( 3): 664- 673. DOI: 10.1097/HEP.0000000000000847.
    [37]
    ANOLLI MP, DEGASPERI E, ALLWEISS L, et al. A 3-year course of bulevirtide monotherapy may cure hdv infection in cirrhotics[J]. J Hepatol, 2023, 78( 4): 876- 880. DOI: 10.1016/j.jhep.2022.12.023.
    [38]
    LOGLIO A, FERENCI P, UCEDA RENTERIA SC, et al. Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients[J]. J Hepatol, 2019, 71( 4): 834- 839. DOI: 10.1016/j.jhep.2019.07.003.
    [39]
    ASSELAH T, LAMPERTICO P, ALEMAN S, et al. Bulevirtide monotherapy is safe and well tolerated in chronic hepatitis delta: An integrated safety analysis of bulevirtide clinical trials at week 48[J]. Liver Int, 2025, 45( 4): e16174. DOI: 10.1111/liv.16174.
    [40]
    WINDISCH MP, UNCHWANIWALA N, LI JC, et al. LBP-001 Preclinical profiling of ABI-6250, a first-in-class oral therapeutic candidate for chronic hepatitis[J]. J Hepatol, 2025, 82: S70. DOI: 10.1016/s0168-8278(25)00420-9.
    [41]
    LIU Y, ZHOU J, MAO F, et al. A novel oral NTCP inhibitor HH-1270 exhibits favorable properties as a clinical candidate for the treatment of HBV/HDV infection[C]// Proceedings of the 2024 International HBV Meeting. Chicago: 2024.
    [42]
    GRIPON P, LE SEYEC J, RUMIN S, et al. Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity[J]. Virology, 1995, 213( 2): 292- 299. DOI: 10.1006/viro.1995.0002.
    [43]
    LE SEYEC J, CHOUTEAU P, CANNIE I, et al. Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain[J]. J Virol, 1999, 73( 3): 2052- 2057. DOI: 10.1128/JVI.73.3.2052-2057.1999.
    [44]
    CHOUTEAU P, LE SEYEC J, CANNIE I, et al. A short N-proximal region in the large envelope protein harbors a determinant that contributes to the species specificity of human hepatitis B virus[J]. J Virol, 2001, 75( 23): 11565- 11572. DOI: 10.1128/JVI.75.23.11565-11572.2001.
    [45]
    BLANCHET M, SUREAU C. Infectivity determinants of the hepatitis B virus pre-S domain are confined to the N-terminal 75 amino acid residues[J]. J Virol, 2007, 81( 11): 5841- 5849. DOI: 10.1128/JVI.00096-07.
    [46]
    LE DUFF Y, BLANCHET M, SUREAU C. The pre-S1 and antigenic loop infectivity determinants of the hepatitis B virus envelope proteins are functionally independent[J]. J Virol, 2009, 83( 23): 12443- 12451. DOI: 10.1128/JVI.01594-09.
    [47]
    SUREAU C, SALISSE J. A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant[J]. Hepatology, 2013, 57( 3): 985- 994. DOI: 10.1002/hep.26125.
    [48]
    LI D, HE WH, LIU XM, et al. A potent human neutralizing antibody Fc-dependently reduces established HBV infections[J]. eLife, 2017, 6: e26738. DOI: 10.7554/eLife.26738.
    [49]
    WANG XR, CHI XM, ZHANG YY, et al. LBP-24 Safety and efficacy of anti-pre-S1 domain monoclonal antibody(HH-003) treatment in patients with co-infection of chronic hepatitis B virus(HBV) and hepatitis D virus(HDV): A single center, open-label, phase 2 trial[J]. J Hepatol, 2023, 78: S117. DOI: 10.1016/S0168-8278(23)00606-2.
    [50]
    SAEED SH, YAO X, ZAIGHAM A, et al. Efficacy and safety of libevitug(HH-003) in patients with chronic hepatitis D virus infection: An international, multicenter, randomized, controlled, open-label phase 2 b Study(H H003- 204)[C]// Proceedings of The Liver Meeting, American Association for the Study of Liver Diseases. Washington, DC: 2025.
    [51]
    LEMPP FA, VOLZ T, CAMERONI E, et al. Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice[J]. J Hepatol, 2023, 79( 5): 1129- 1138. DOI: 10.1016/j.jhep.2023.07.003.
    [52]
    RAMOS H, ALCALA R, MICHELET M, et al. WED-366 Characterization of BJT-778, an anti-HBsAg neutralizing monoclonal antibody for treatment of hepatitis B virus and hepatitis D virus infections[J]. J Hepatol, 2024, 80: S808. DOI: 10.1016/S0168-8278(24)02233-5.
    [53]
    ASSELAH T, CHATTERGOON MA, JUCOV A, et al. A phase 2 trial of tobevibart plus elebsiran in hepatitis D[J]. N Engl J Med, 2026, 394( 4): 343- 353. DOI: 10.1056/nejmoa2508827.
    [54]
    AGARWAL K, DOBRYANSKA M, JUCOV A, et al. BJT-778, anti-HBsAg monoclonal antibody, achieved 100% virologic response in subjects with chronic hepatitis D(CHD): Phase 2 study results[C]// Proceedings of The Liver Meeting, American Association for the Study of Liver Diseases. San Diego, CA: 2024.
    [55]
    AGARWAL K, JUCOV A, DOBRYANSKA M, et al. Brelovitug(BJT-778) monotherapy achieved 100% virologic response in patients with chronic hepatitis D: On treatment week 48 phase 2 study results[C]// Proceedings of The Liver Meeting, American Association for the Study of Liver Diseases. Washington, DC: 2025.
    [56]
    RIZZETTO M, HOYER B, CANESE MG, et al. Delta Agent: Association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees[J]. Proc Natl Acad Sci USA, 1980, 77( 10): 6124- 6128. DOI: 10.1073/pnas.77.10.6124.
    [57]
    WANG CJ, CHEN PJ, WU JC, et al. Small-form hepatitis B surface antigen is sufficient to help in the assembly of hepatitis delta virus-like particles[J]. J Virol, 1991, 65( 12): 6630- 6636. DOI: 10.1128/JVI.65.12.6630-6636.1991.
    [58]
    YURDAYDIN C, KESKIN O, KALKAN Ç, et al. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study[J]. Hepatology, 2018, 67( 4): 1224- 1236. DOI: 10.1002/hep.29658.
    [59]
    ETZION O, HAMID SS, ASSELAH T, et al. GS-012 Week 48 results of the phase 3 D-LIVR study, a randomized double-blind, placebo-controlled trial evaluating the safety and efficacy of Lonafarnib-boosted with Ritonavir with or without Peginterferon Alfa in patients with chronic hepatitis delta[J]. J Hepatol, 2023, 78: S10. DOI: 10.1016/S0168-8278(23)00451-8.
    [60]
    VAILLANT A. Oligonucleotide-based therapies for chronic HBV infection: A primer on biochemistry, mechanisms and antiviral effects[J]. Viruses, 2022, 14( 9): 2052. DOI: 10.3390/v14092052.
    [61]
    ASSELAH T, STREINU-CERCEL A, JUCOV A, et al. OS-127 Efficacy and safety of tobevibart(VIR-3434) alone or in combination with elebsiran(VIR-2218) in participants with chronic hepatitis delta virus infection: Preliminary results from the phase 2 SOLSTICE trial in non-cirrhotic and compensated cirrhotic participants[J]. J Hepatol, 2024, 80: S75- S76. DOI: 10.1016/S0168-8278(24)00565-8.
    [62]
    WOODDELL C, ZHU R, HAMILTON H, et al. Development of subcutaneously administered RNAi therapeutic ARO-HBV for chronic hepatitis B virus infection[J]. J Hepatol, 2018, 68: S18- S19. DOI: 10.1016/s0168-8278(18)30255-1.
    [63]
    SETO WK, LIANG ZC, GAN LM, et al. SAT-172 Safety and antiviral activity of RBD1016, a RNAi therapeutic, in Chinese subjects with chronic hepatitis B virus(HBV) infection[J]. J Hepatol, 2023, 78: S1152. DOI: 10.1016/S0168-8278(23)03287-7.
    [64]
    WEDEMEYER H, LAMPERTICO P, GANE EJ, et al. LBP-044 Robust reduction of HBsAg and HDV RNA levels with low risk for ALT elevations in JNJ-73763989 treated patients with chronic hepatitis D(CHD) and baseline HBsAg levels below 10, 000 IU/mL: Part 2 of the REEF-D study[J]. J Hepatol, 2024, 80: S100. DOI: 10.1016/s0168-8278(24)00611-1.
    [65]
    BAZINET M, PÂNTEA V, PLACINTA G, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon Alfa-2a in patients with chronic HBV infection Naïve to nucleos(t)ide therapy[J]. Gastroenterology, 2020, 158( 8): 2180- 2194. DOI: 10.1053/j.gastro.2020.02.058.
    [66]
    BAZINET M, PÂNTEA V, CEBOTARESCU V, et al. Safety and efficacy of REP 2139 and pegylated interferon Alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection(REP 301 and REP 301-LTF): A non-randomised, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2017, 2( 12): 877- 889. DOI: 10.1016/S2468-1253(17)30288-1.
    [67]
    BAZINET M, PÂNTEA V, CEBOTARESCU V, et al. Persistent control of hepatitis B virus and hepatitis delta virus infection following REP 2139-Ca and pegylated interferon therapy in chronic hepatitis B virus/hepatitis delta virus coinfection[J]. Hepatol Commun, 2020, 5( 2): 189- 202. DOI: 10.1002/hep4.1633.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (29) PDF downloads(13) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return